MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer’s Disease Phenotypes

(2018) Hsueh-Yun Lee et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease

(2018) Maria Cosenza et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Proteostasis regulation by the ubiquitin system

(2016) J. S. Bett   Essays in Biochemistry

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

(2016) Teru Hideshima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives

(2016) Nuggehally R. Srinivas   XENOBIOTICA

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death

(2015) Yuko Mishima et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

(2015) J. E. Amengual et al.   CLINICAL CANCER RESEARCH

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

(2015) J Laubach et al.   LEUKEMIA

Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis

(2015) Yen-Chia Huang et al.   Oncotarget

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes

(2015) Paul G Richardson et al.   Expert Review of Clinical Pharmacology

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells

(2014) J. Wang et al.   BLOOD

Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells

(2014) Ning Ding et al.   Cancer Cell International

Interplay Between HDAC6 and Its Interacting Partners: Essential Roles in the Aggresome-Autophagy Pathway and Neurodegenerative Diseases

(2014) Jin Yan   DNA AND CELL BIOLOGY

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Sequence analysis of  -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

(2012) D. I. Lichter et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes

(2012) Yingxiu Li et al.   FEBS Journal

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

(2010) Sundar Jagannath et al.   LEUKEMIA RESEARCH

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

(2010) Eric Sanchez et al.   LEUKEMIA RESEARCH

Histone deacetylases and epigenetic therapies of hematological malignancies

(2010) Ciro Mercurio et al.   PHARMACOLOGICAL RESEARCH

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells

(2008) U. Mahlknecht et al.   HAEMATOLOGICA

Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally

(2008) Y. Zhang et al.   MOLECULAR AND CELLULAR BIOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE